Cargando…
RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
BACKGROUND: Facioscapulohumeral dystrophy (FSHD) is caused by mutations leading to the aberrant expression of the DUX4 transcription factor in muscles. DUX4 was proposed to induce cell death, but the involvement of different death pathways is still discussed. A possible pro‐apoptotic role of DUX4 wa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718031/ https://www.ncbi.nlm.nih.gov/pubmed/34687171 http://dx.doi.org/10.1002/jcsm.12813 |
_version_ | 1784624634665107456 |
---|---|
author | Mariot, Virginie Joubert, Romain Le Gall, Laura Sidlauskaite, Eva Hourde, Christophe Duddy, William Voit, Thomas Bencze, Maximilien Dumonceaux, Julie |
author_facet | Mariot, Virginie Joubert, Romain Le Gall, Laura Sidlauskaite, Eva Hourde, Christophe Duddy, William Voit, Thomas Bencze, Maximilien Dumonceaux, Julie |
author_sort | Mariot, Virginie |
collection | PubMed |
description | BACKGROUND: Facioscapulohumeral dystrophy (FSHD) is caused by mutations leading to the aberrant expression of the DUX4 transcription factor in muscles. DUX4 was proposed to induce cell death, but the involvement of different death pathways is still discussed. A possible pro‐apoptotic role of DUX4 was proposed, but as FSHD muscles are characterized by necrosis and inflammatory infiltrates, non‐apoptotic pathways may be also involved. METHODS: We explored DUX4‐mediated cell death by focusing on the role of one regulated necrosis pathway called necroptosis, which is regulated by RIPK3. We investigated the effect of necroptosis on cell death in vitro and in vivo experiments using RIPK3 inhibitors and a RIPK3‐deficient transgenic mouse model. RESULTS: We showed in vitro that DUX4 expression causes a caspase‐independent and RIPK3‐mediated cell death in both myoblasts and myotubes. In vivo, RIPK3‐deficient animals present improved body and muscle weights, a reduction of the aberrant activation of the DUX4 network genes, and an improvement of muscle histology. CONCLUSIONS: These results provide evidence for a role of RIPK3 in DUX4‐mediated cell death and open new avenues of research. |
format | Online Article Text |
id | pubmed-8718031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87180312022-01-06 RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy Mariot, Virginie Joubert, Romain Le Gall, Laura Sidlauskaite, Eva Hourde, Christophe Duddy, William Voit, Thomas Bencze, Maximilien Dumonceaux, Julie J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Facioscapulohumeral dystrophy (FSHD) is caused by mutations leading to the aberrant expression of the DUX4 transcription factor in muscles. DUX4 was proposed to induce cell death, but the involvement of different death pathways is still discussed. A possible pro‐apoptotic role of DUX4 was proposed, but as FSHD muscles are characterized by necrosis and inflammatory infiltrates, non‐apoptotic pathways may be also involved. METHODS: We explored DUX4‐mediated cell death by focusing on the role of one regulated necrosis pathway called necroptosis, which is regulated by RIPK3. We investigated the effect of necroptosis on cell death in vitro and in vivo experiments using RIPK3 inhibitors and a RIPK3‐deficient transgenic mouse model. RESULTS: We showed in vitro that DUX4 expression causes a caspase‐independent and RIPK3‐mediated cell death in both myoblasts and myotubes. In vivo, RIPK3‐deficient animals present improved body and muscle weights, a reduction of the aberrant activation of the DUX4 network genes, and an improvement of muscle histology. CONCLUSIONS: These results provide evidence for a role of RIPK3 in DUX4‐mediated cell death and open new avenues of research. John Wiley and Sons Inc. 2021-10-22 2021-12 /pmc/articles/PMC8718031/ /pubmed/34687171 http://dx.doi.org/10.1002/jcsm.12813 Text en © 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Mariot, Virginie Joubert, Romain Le Gall, Laura Sidlauskaite, Eva Hourde, Christophe Duddy, William Voit, Thomas Bencze, Maximilien Dumonceaux, Julie RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy |
title | RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy |
title_full | RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy |
title_fullStr | RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy |
title_full_unstemmed | RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy |
title_short | RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy |
title_sort | ripk3‐mediated cell death is involved in dux4‐mediated toxicity in facioscapulohumeral dystrophy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718031/ https://www.ncbi.nlm.nih.gov/pubmed/34687171 http://dx.doi.org/10.1002/jcsm.12813 |
work_keys_str_mv | AT mariotvirginie ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT joubertromain ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT legalllaura ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT sidlauskaiteeva ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT hourdechristophe ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT duddywilliam ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT voitthomas ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT benczemaximilien ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy AT dumonceauxjulie ripk3mediatedcelldeathisinvolvedindux4mediatedtoxicityinfacioscapulohumeraldystrophy |